Modifiable Cardiovascular Risk and the Efficacy of Icosapent Ethyl: A REDUCE-IT Secondary Analysis - 07/08/25
Doi : 10.1016/j.hlc.2025.06.537
G. Figtree 1, R. Aggarwal 2, D. Bhatt 3, M. Miller 4, C. Ballantyne 5, E. Brinton 6, T. Jacobson 7, S. Ketchum 8, J. Tardif 9, M. Budoff 10, P. Steg 11
1 The University of Sydney, Sydney, NSW, Australia
2 Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA
3 Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA
4 Department of Medicine, Crescenz Veterans Affairs Medical Center and University of Pennsylvania School of Medicine, Philadelphia, PA, USA
5 Department of Medicine, Baylor College of Medicine, and the Texas Heart Institute, Houston, TX, USA
6 Utah Lipid Center, Salt Lake City, UT, USA
7 Lipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
8 Amarin Pharma, Inc., Bridgewater, NJ, USA
9 Montreal Heart Institute, Université de Montréal, Montreal, Québec, Canada
10 Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, USA
11 Université Paris-Cité, Assistance Publique-Hôpitaux de Paris and INSERM U1148, Paris, France
521
Il testo completo di questo articolo è disponibile in PDF.Mappa
© 2025
Pubblicato da Elsevier Masson SAS.
Vol 34 - N° S4
P. S429-S430 - agosto 2025 Ritorno al numero
Articolo precedente
- Mineralocorticoid Receptor Antagonist Prescription Patterns Post-STEMI: A Single-Centre Quality Improvement Audit From An Australian Tertiary Hospital
- P. Brown, J. Shute, R. Lambert, P. Dhonde, R. Jayasinghe
- My Ears Were Rocking
- K. Peiris, L. Chean, S. Sidharta, R. Garg
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?